The aim of the present study was to examine the excess relative risk for leukemia mortality and all cancers, except leukemia, among Hiroshima atomic-bomb survivors by applying ABS93D and ABS2000D. Particular attention was given to any difference in the neutron-dose estimates between the two dosimetry systems. The study subjects were 51,532 atomic-bomb survivors registered in a database of the Research Institute for Radiation Biology and Medicine of Hiroshima University (RIRBM). The results obtained by both dosimetry systems are similar: the excess relative risk per Sv for leukemia mortality and all cancers except leukemia is significantly higher compared to the control group. In addition, the difference in the excess relative risks between the two systems is not significant. Therefore, it is indicated that a modification of the neutron-dose estimates would not markedly change the conclusions about the cancer mortality risk.
INTRODUCTION
The radiation doses for atomic-bomb survivors in Hiroshima and Nagasaki were estimated based on *Corresponding author: Phone; +81-82-261-1953, FAX; +81-82-261-4086, E-mail; H_katayama@rerf.jp the Dosimetry System 1986 (DS86) by the Radiation Effects Research Foundation (RERF). However, the survivors evaluated by DS86 were limited to those registered at RERF, and the doses of many other survivors (at least 30% or more of all the survivors) had not yet been determined. It was necessary for the Research Institute for Radiation Biology and Medicine of Hiroshima University (RIRBM) to obtain radiation doses for each survivor in order to estimate the risks for any acute or late radiation effects, and to draw out a complete clinical picture for each individual survivor. Therefore, the Atomic Bomb Survivors 1993 Dosimetry System (ABS93D) was established 1) . The ABS93D adopted at RIRBM was essentially based on the final report of DS86 2) , and provided the free-in-air (FIA) kerma, shielding kerma and organabsorbed dose based on the individual exposure status, including the ground distance from the hypocenter, shielding condition and subject's age at the time of the bombing.
However, the neutron-dose estimates came into question because of a gap between the radionuclide activation yields in materials exposed to neutrons from the Hiroshima atomic bomb and the estimated activation based on DS86. Hoshi et al. proved that there is a systematic difference between the estimated dose by DS86 and the radiation dose measured from exposed samples [3] [4] . Since the radiation dose measured from exposed samples taken 1 km from the hypocenter was two to ten-times higher than the estimated dose by DS86, Hoshi et al. inferred that the actual radiation dose was much higher than those estimated in the past. They argued that the cause of this high dose was a horizontal crack in the atomic bomb, out of which prompt neutrons had leaked in the horizontal direction. As a result, the formation of 152 Eu, 60 Co, 36 CI and 32 P may have increased and, in addition, the yield of the Hiroshima atomic bomb may have been increased by 20% due to an increase of about 90 m in elevation of the neutron emission point 3) . This issue is still being examined by Japanese and American scientists, and one solution has been proposed in an article, "A Crack Model of the Hiroshima Atomic Bomb: Explanation of the Contradiction of Dosimetry System 1986'" 5) . Based on the hypothesis of the crack model, a new dosimetry system, the Atomic B o m b S u r v i v o r s 2 0 0 0 D o s i m e t r y S y s t e m (ABS2000D), was established. The present study is the first attempt to apply ABS2000D to subjects selected from the RIRBM database, to compare its results with those of ABS93D, and to investigate the effects of the increased neutron dose estimated by ABS2000D on the estimated cancer mortality risk.
MATERIALS AND METHODS

Subjects of this study
The surveyed group at RIRBM consisted of all survivors living in Hiroshima Prefecture. In 1997, the number of survivors who were registered in the RIRBM database was approximately 250,000 [6] [7] .
Information regarding the deaths was obtained from Vital Statistics Death Schedules authorized by the Prime Minister's Office, which is based on official death certificates kept at the Health Center of the region where the death occurred. Validation of deaths was limited to those living in Hiroshima Prefecture from 1968 to 1997 with complete information on the causes of death. Therefore, we defined the observation period for the present study to be from January 1, 1968 to December 31, 1997. Because the aim of the present study was to compare the risk estimates using ABS2000D with those using ABS93D, the subjects eligible for this study were survivors who were alive on January 1, 1968, and to whom a dose estimation by both systems could be applied. The procedure for selecting the subjects was as follows: from the 250,000 survivors registered with the RIRBM database, we excluded 100,000 early entrants after the bombing, and 20,000 survivors exposed in-utero or indirectly, in order to obtain those who were directly exposed. Then, from the remaining 130,000 directly exposed survivors, we excluded those survivors whose precise location and conditions of exposure were unknown, and those protected by sturdy shielding, such as concrete buildings, because a method for estimating the dose had not yet been established for them. We also excluded those who had died before 1968 because the cause of their death was not clear, and we therefore considered them to be inappropriate for the present study, which was to evaluate the relative mortality risk for leukemia and for all cancers except leukemia. Finally, non-Japanese persons were excluded from this study group. After all of these exclusions, the total number of subjects included in the present analysis was 51,532, of which 30,305 were female.
The exposed group was defined as having received a radiation dose greater than 0.005 Sv, and the control group a dose equal to or lower than 0.005 Sv. Table 1 indicates the number of subjects, personyears, number of deaths from leukemia and the number of deaths from all cancers, except leukemia, during the observation period from 1968 to 1997 according to the ABS2000D organ dose. Among the 51,532 subjects, 128 deaths from leukemia were observed, of which 59 were female, and 4,798 deaths from all cancers except leukemia, of which 2,340 were female.
Causes of death
The causes of death shown in the death certificates were encoded according to the 8 
Radiation dose
Based on the final report of DS86 2) , RIRBM established its own dosimetry system, ABS93D, to estimate the organ-absorbed doses as accurately as possible. In order to estimate the bone-marrow and large-intestine doses for each survivor, the following accurate information was necessary: (1) the precise location when exposed (because a difference of 50 m causes an approximately 23% change in the FIA kerma dose estimated by DS86), (2) whether the person was outside or inside a Japanese wooden house, and (3) the subject's age at the time of the bombing. In a joint study 8) conducted by RERF and RIRBM, each institute randomly selected 10,000 persons from their survey population to be subjects for the study, and by using DS86 and ABS93D, examined the given doses, such as bone marrow dose, female breast dose, and the large intestine dose, of the same subjects in both surveyed populations. This study proved that the results of the ABS93D estimations were close to those of DS86, and that the difference in the dose estimates given by the two dosimetry systems is less than 10%. Hoshi et al. established ABS2000D in order to explain the differences between the radiation dose measured from the exposed samples and the estimated dose by DS86. The computer source code used for ABS2000D was a Monte Carlo source code (MCNP-4B) 9) that includes the neutron cross-section library ENDF-V, VI, as shown in Hoshi et al. 10) . The values of prompt neutron rays, prompt gamma rays and prompt secondary gamma rays were provided by this estimation, and the values given by DS86 were used for delayed gamma rays and delayed neutron rays.
The radiation doses for FIA kerma, classified by distance from the hypocenter, which were estimated by DS86 and ABS2000D, are indicated in Figure 1 . The FIA kerma gamma rays estimated by ABS2000D at 1,000 m was 1.12-times higher than those by DS86, and at 2,000 m 1.15-times higher; however, the difference in the values given by the two dosimetry systems is fairly stable regardless of the ground distance from the hypocenter. On the other hand, with regard to the FIA kerma neutron dose, the neutron dose estimated by ABS2000D was lower than that by DS86 within a short distance from the hypocenter, but equal at 300 m from the hypocenter. The FIA kerma neutron dose given by ABS2000D at 1,000 m was 2.4-times higher than that by DS86, and at 2,000 m 3.9-times higher. The difference in the FIA kerma neutron dose between DS86 and ABS2000D increased in proportion to the distance from the hypocenter, and the FIA kerma neutron dose given by ABS2000D was closer to that measured from the exposed samples.
When the value of RBE was 30, the average was *large intestine dose **bone marrow dose 0.292 Gy with ABS93D and 0.416 Gy with ABS2000D (1.42-times higher). In the present study, the bonemarrow dose was used for analyzing the leukemia mortality and the large intestine dose was used for analyzing the mortality due to all cancers except leukemia.
Statistical methods
We adopted the Poisson Regression Analysis 11) in order to compare the relative risks of the atomic bomb survivors. Letting i=1, …, I being the index strata, which are defined here by a cross-classification based on sex, age at the time of the bombing (< 10 years old, 10-19, 20-29, 30-39, 40-49, 50+) and the follow-up intervals (1968-1972, 1973-1977, 1978-1982, 1983-1987, 1988-1992, 1993-1997) .
We also let j = 0, …, J-1 be the exposure categories.
In this analysis, we used J = 10 exposure groups (0 -0.004Sv, 0.005-0.05Sv, 0.06-0.09Sv, 0.10-0.19Sv, 0.20 -0.49Sv, 0.50-0.99Sv, 1.00-1.99Sv, 2.00-2.99Sv, 3.00-3.99Sv, 4.00+Sv), where the 0-0.004 Sv group is the control group (0Sv). Furthermore, we defined Y ij , PY ij , M ij to be the number of deaths, person-years, and mortality rates, respectively, in stratum i and dose group j. Thus, the mortality rate, M ij , in the i-th stratum and j-th dose category can be assumed to be M ij = Mi0 x RR ij . Mi0 represents the background or spontaneous mortality rate of stratum i, namely the mortality rate of those that were not exposed to radiation from the atomic bomb. RR ij is the relative risk in stratum i of the exposure group j, which pertains to the risk of the 0Sv control group with the background mortality rate compensated by sex, age at the time of the bombing and the time that elapsed since exposure to radiation.
Furthermore, the relative risk, RR ij , was modeled as RR ij = 1+bDij. Here, b is an unknown parameter indicating the average excess relative risk per Sv over all strata.
In order to estimate the relative risk by sex, the model was applied separately to males and females. An analysis separated by exposed groups used a model with a relative risk of RR ij = exp(b j ). The parameters were estimated by the maximum-likelihood method, assuming that the numbers of deaths, Y ij , are an independent Poisson Distribution with the expected values, E(Y ij ) = PY ij x M ij x RR ij , where PY ij is considered to be a constant. The calculation of person-years was based on the subject's duration of residence in Hiroshima Prefecture with consideration to migration into and out of the prefecture. Subjects that moved out of Hiroshima prefecture were treated as being lost to a follow-up at the time of migration. For the actual analysis, the AMFIT program in the EPICURE 12) statistics package was used.
RESULTS
Distribution of the subject group according to the dosimetry system
The variations in the distribution according to ABS93D and ABS2000D are given in Table 2 . When RBE =1, 80% of the subjects were classified into the same categories according to both dosimetry systems, but of the remaining 20% of the subjects, the ABS2000D group had been classified into a higher dose category than that of the ABS93D group.
Particularly, as the dose became higher, the ratio of the transition also became higher, and 62.9% of the subjects classified into the dose category of 3.00 -3.99 Sv by the ABS93D were classified into the dose category of over 4.00 Sv by ABS2000D. Table 3 gives comparisons of the excess relative risk (ERR) between 1968 and 1997 according to the dosimetry system, sex, leukemia or non-leukemia, and RBE. The ERR per Sv for leukemia in the total population when RBE=1, was 1.62 (95% Confidence Interval (CI): 0.65-2.56) with ABS93D and 1.34 (95% CI: 0.53-2.15) with ABS2000D. The ERR was significantly higher in both dosimetry systems, compared to the control group, that is, the 0 Sv exposed group. With regard to the ERR for leukemia by sex, for RBE=1 with ABS93D, the ERR for males was 1.64 (95% CI: 0.38-2.90) and that for females was 1.59 (95% CI: 0.08-3.10); when estimated by ABS2000D, the ERR for males was 1.36 (95% CI: 0.30-2.42) and that for females was 1.31 (95% CI: 0.26-2.57). No significant difference was observed between the two dosimetry systems, nor between the sexes.
Excess relative risk per Sv for cancer mortality (organ dose)
For all cancers except leukemia, when RBE=1, the ERR estimated by ABS93D was 0.24 (95%CI: 0.18-0.32), and that estimated by ABS2000D was 0.22 (95% CI: 0.16-0.28). With regard to the ERR for all cancers except leukemia by sex, for RBE=1 with ABS93D, the ERR for males was 0.12 (95% CI: 0.05-0.19) and that for females was 0.50 (95% CI: 0.35-0.64); when estimated by ABS2000D, the ERR for males was 0.12 (95% CI: 0.05-0.19) and that for females was 0.42 (95% CI: 0.30-0.54). There were no significant differences for all cancers except leu- kemia from the two dosimetry systems; however, for the difference with regard to sex, the ERR for females was higher than that for males in both dosimetry systems. The value of the ERR for leukemia was inversely related to the value of RBE in both doseestimation systems. With ABS93D, it was from 1.62 for RBE=1 (95%CI: 0.65-2.56), to 1.08 for RBE=30 (95%CI: 0.44 -1.72); and with ABS2000D it was from 1.34 for RBE=1 (95%CI: 0.53-2.15) to 0.81 for RBE=30 (95%CI: 0.34-1.28).
The ERR for all cancers except leukemia scarcely changed with the RBE value. With ABS93D, the ERR varied from 0. Table 4 gives the estimated relative risks of mortality in the exposed groups from 1968 to 1997, which were estimated by ABS2000D. The relative risk (RR) for leukemia in the dose category group of over 1-1.99 Sv, when RBE=1, increased significantly to 3.01 (95%CI: 1.68-5.38). The RR for leukemia in the 3.0 -3.99 dose group was 3.10 (95%CI: 0.74 -12.88), but was not significant. For all cancers except leukemia in the dose category group of over 0.2-0.49 Sv, when RBE=1, the RR increased significantly to 1.19 (95%CI: 1.09-1.29). When the RBE was considered, a significant relative risk for leukemia was observed at over 1 Sv when RBE=1, and at over 2 Sv when RBE was over 10. For all cancers except leukemia, a significant relative risk was observed at over 0.2 Sv when RBE=1 and over 10. In addition, the relative risks of mortality by dose group according to ABS93D were similar to those obtained by ABS2000D. Table 5 gives the ERR per Sv of an organ dose according to the age at the time of the bombing, which was estimated by ABS2000D. For leukemia, a high ERR was observed in the age group < 10 years old without regard to an increase in the RBE, but was not significant. In the other age groups, some differences were observed, but they were not significant, either. For all cancers except leukemia, without regard to an increase in the RBE, higher ERRs were observed in the age groups < 40 years old, while no significant increase in the risk was observed in the age group > 40 years old. Even in the age groups < 40 years old, a tendency toward a slightly higher ERR was observed. In estimations using ABS93D, similar results were obtained.
Estimated relative risks in the exposed groups of cancer mortality (organ dose)
Excess relative risk of mortality per Sv by age at the time of the bombing
DISCUSSION
In this study, we compared the relative mortality risks for cancers by using two dosimetry systems, ABS93D and ABS2000D. We selected as a cohort 51,532 subjects from the Hiroshima atomic-bomb survivors registered in the RIRBM database, and examined the relative risks for cancers classified into two categories, that is, leukemia, and all cancers except leukemia. Particular attention was given to the fact that the estimation by ABS2000D provides larger neutron-dose estimates than those of ABS93D.
The results obtained by both dosimetry systems show a significant excess relative risk per Sv for leukemia mortality and all cancers except leukemia, compared to the control group, but the difference of the excess relative risks between the two systems is not significant. Therefore, it is indicated that a modification of the neutron-dose estimates would not markedly change the conclusions.
However, there are some pointes to be considered carefully. First is the difference in the excess relative risk (ERR) for all cancers except leukemia between males and females. Though there was no marked difference in the ERR between males and females for leukemia, a higher ERR was observed with females than with males for all cancers except leukemia. However, since the mortality rate for all cancers except leukemia per 10,000 person-years was 1.37 for both males and females, the higher ERR observed for females could be due to a significantly lower value for the cancer background mortality rate for females as compared to males 13) . Second is the estimated neutron relative biological effectiveness (RBE). Neutron rays generally have a larger RBE [14] [15] per dose unit than gamma rays.
Therefore, in considering the effects of neutron rays on the survivors, we assumed the RBE of the neutron dose to be 1, 10, 20 and 30 in order to bring the value closer to the equivalent biological effect of the gamma dose. Researchers have given different definitions of RBE, and have not yet reached a satisfactory conclusion [16] [17] [18] [19] . When ABS93D was used, the effect of an increase in the RBE, that is, a decrease in the ERR was observed for the leukemia, but was not especially remarkable. An increase in the RBE did not lead to any significant change of the ERR for all cancers except leukemia. When ABS2000D was used, an increase in the RBE led to a decrease in the ERR for leukemia, as was observed with the estimation by ABS93D. However, in the estimation by ABS2000D, for all cancers except leukemia, there was a tendency toward a lower ERR when RBE became 20 or more. It is difficult to say whether this decreasing trend is significant compared with ABS93D. However, since it was demonstrated that, of all the solid cancers, the relative risks of lung, colon and female breast cancers are significantly higher than the others [20] [21] , it might be suggested that the relative risks of these cancers correspond to the increase in the total dose by the RBE. Little 16) examined the neutron RBE for the two classified cancers, and reported that the RBE for solid cancers is lower than that of leukemia, but it might be one attempt to classify cancers into three categories, that is, (1) lung, colon, and female breast cancers, (2) other solid cancers, and (3) leukemia, and examine the RBE for them. Third is the definition of the proximal exposure. This is defined as exposure within a 2 km range from the hypocenter, but also defined as an estimated dose of over 0.005 Sv according to the Tentative 1965 Dose Revised (T65DR), which is the estimated dose for a small mass of biological tissue estimated based on the exposure location and shielding, as was used until the early 1980s 22) . The latter definition was adopted in Hiroshima, and those exposed within an approximately 2.4 km range from the hypocenter are defined as proximally exposed 23) . Assuming that the dose estimates are identical, the estimation by ABS2000D leads to a distance increase of approximately 200 to 300 meters from the hypocenter, compared to ABS93D.
Nevertheless, the organ dose measurement should take into consideration the subject's age at the time of the bombing and the shielding conditions in addition to distance. For example, for radiation exposure in a factory, the shielding effects of the worktables, tools and the like must be considered. For exposure within a house, the shielding protection from other neighboring houses two-times taller than the one inhabited at the time of the bombing should also be taken into consideration. Furthermore, when examining the differences in the shielding conditions, such as the variations in elevation and the shelter of such geographical features as mountains, a threedimensional model should be used for estimating the shielding conditions.
In order to acquire enhanced, accurate data concerning the effects of radiation exposure on the human body, a more exact estimation method needs to be established which would provide the estimated values corresponding with the actual values over a wide dose range and takes into consideration the shielding conditions of the radiation exposed. At the same time, it is vital to have methods for obtaining precise input data, because there are now large uncertainties in the input data stemming from the limitations, inaccuracies and imprecision of self-reports and data on shielding configurations. These issues should be further investigated in the near future. 
